The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.125
Bid: 3.00
Ask: 3.25
Change: -0.175 (-5.30%)
Spread: 0.25 (8.333%)
Open: 3.075
High: 3.38
Low: 3.10
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI)

25 Oct 2023 09:48

RNS Number : 2658R
Cavendish Securities PLC
25 October 2023

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

24/10/23

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

ORD 0.1p

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

279288

0.01

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

279288

0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 0.1p

Sales

4000

1.57

1.57

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

25/10/23

Contact name:

Angela Teodorescu

Telephone number:

02037724641

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FEOUVSWROBURURA
Date   Source Headline
1st Oct 201412:30 pmRNSTotal Voting Rights
30th Sep 20147:00 amRNSAmendment of 2012 Loan Note term
29th Sep 201410:52 amRNSHolding(s) in Company
24th Sep 20141:18 pmRNSExercise of Options
24th Sep 201412:12 pmRNSAnnual Report and Accounts
22nd Sep 20147:00 amRNSFinal Results
4th Sep 20147:00 amRNSShareholder update
24th Jul 20147:00 amRNSNotice of Results and Trading Update
17th Jul 20143:10 pmRNSHolding(s) in Company
30th Apr 20147:01 amRNSWorthing Facility Licence Renewal
25th Apr 20147:00 amRNSDirector/PDMR Shareholding
17th Apr 20147:00 amRNSExtension of Convertible Loan Note
24th Mar 20147:00 amRNSHalf Yearly Report
17th Mar 20147:00 amRNSNotice of Results
12th Mar 20147:00 amRNSShareholder update
19th Feb 20147:00 amRNSHealth Canada approves submission of CTA
27th Jan 20147:00 amRNSResults published in highly respected journal
14th Jan 20147:00 amRNSTrading Update and Notice of Results
20th Nov 20131:19 pmRNSResult of AGM
20th Nov 20137:00 amRNSBusiness and R&D Update
16th Oct 20134:21 pmRNSAnnual Report and Accounts
9th Oct 20138:48 amRNSNotification under AIM Rule Schedule Two (g)
27th Sep 20138:33 amRNSChange of Adviser
19th Sep 20133:51 pmRNSHolding(s) in Company
16th Sep 20137:00 amRNSFinal Results
3rd Jun 201310:23 amRNSHolding(s) in Company
15th May 201310:20 amRNSGrant of Options
8th May 201310:39 amRNSHolding(s) in Company
8th May 201310:18 amRNSHolding(s) in Company
25th Mar 20137:00 amRNSHalf Yearly Report
11th Mar 20137:00 amRNSNotice of results and shareholder update
11th Mar 20137:00 amRNSUS patent granted
22nd Jan 201310:41 amRNSExercise of Options
28th Dec 20127:00 amRNSTotal Voting Rights
27th Dec 201212:02 pmRNSUpdate on Lincoln Medical Final
19th Dec 20123:14 pmRNSGrant of Options
10th Dec 201211:44 amRNSDirector/PDMR Shareholding
5th Dec 20123:42 pmRNSTotal Voting Rights
4th Dec 201212:40 pmRNSExercise of Options
30th Nov 20129:00 amRNSTotal Voting Rights
21st Nov 20122:23 pmRNSHolding(s) in Company
20th Nov 20122:25 pmRNSExercise of Options
14th Nov 201211:41 amRNSResult of AGM
9th Nov 201212:12 pmRNSDirector/PDMR Shareholding
16th Oct 20123:54 pmRNSAnnual Financial Report
4th Oct 20123:57 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSFinal Results
30th Aug 201211:14 amRNSNotice of results and shareholder update
3rd Aug 20127:00 amRNSFDA Clinical Hold Lifted
31st May 20122:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.